EP1067954A4 - Utilisation d'anticorps anti-gp39 pour traiter et/ou faire regresser un lupus et une maladie renale associee - Google Patents

Utilisation d'anticorps anti-gp39 pour traiter et/ou faire regresser un lupus et une maladie renale associee

Info

Publication number
EP1067954A4
EP1067954A4 EP99915237A EP99915237A EP1067954A4 EP 1067954 A4 EP1067954 A4 EP 1067954A4 EP 99915237 A EP99915237 A EP 99915237A EP 99915237 A EP99915237 A EP 99915237A EP 1067954 A4 EP1067954 A4 EP 1067954A4
Authority
EP
European Patent Office
Prior art keywords
lupus
reversal
antibodies
treatment
kidney disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99915237A
Other languages
German (de)
English (en)
Other versions
EP1067954A1 (fr
Inventor
Randolph J Noelle
Christopher M Burns
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dartmouth College
Original Assignee
Dartmouth College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dartmouth College filed Critical Dartmouth College
Publication of EP1067954A1 publication Critical patent/EP1067954A1/fr
Publication of EP1067954A4 publication Critical patent/EP1067954A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
EP99915237A 1998-04-03 1999-04-02 Utilisation d'anticorps anti-gp39 pour traiter et/ou faire regresser un lupus et une maladie renale associee Withdrawn EP1067954A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5448898A 1998-04-03 1998-04-03
US54488 1998-04-03
PCT/US1999/007321 WO1999051258A1 (fr) 1998-04-03 1999-04-02 Utilisation d'anticorps anti-gp39 pour traiter et/ou faire regresser un lupus et une maladie renale associee

Publications (2)

Publication Number Publication Date
EP1067954A1 EP1067954A1 (fr) 2001-01-17
EP1067954A4 true EP1067954A4 (fr) 2004-08-18

Family

ID=21991433

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99915237A Withdrawn EP1067954A4 (fr) 1998-04-03 1999-04-02 Utilisation d'anticorps anti-gp39 pour traiter et/ou faire regresser un lupus et une maladie renale associee

Country Status (9)

Country Link
EP (1) EP1067954A4 (fr)
JP (1) JP2002510643A (fr)
KR (1) KR20010072564A (fr)
CN (2) CN100352497C (fr)
AU (1) AU743824B2 (fr)
HU (1) HUP0101689A3 (fr)
NO (1) NO20004966L (fr)
TW (1) TWI224969B (fr)
WO (1) WO1999051258A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41459A (fr) 2015-02-03 2017-12-12 Als Therapy Development Inst Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
CN107921128B (zh) 2015-08-05 2022-04-26 詹森生物科技公司 抗cd154抗体及其使用方法
KR20200010294A (ko) 2017-05-24 2020-01-30 에이엘에스 테라피 디벨럽먼트 인스티튜트 치료용 항-cd40 리간드 항체

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0555880A2 (fr) * 1992-02-14 1993-08-18 Bristol-Myers Squibb Company Récepteur CD40CR et ses ligands
WO1997017446A2 (fr) * 1995-11-07 1997-05-15 Idec Pharmaceutical Corporation ANTICORPS HUMANISES DIRIGES CONTRE LA gp39 D'ORIGINE HUMAINE, COMPOSITIONS CONTENANT CES ANTICORPS ET LEUR UTILISATION THERAPEUTIQUE
WO1998030240A1 (fr) * 1997-01-10 1998-07-16 Biogen, Inc. Traitement de la nephropathie lupique a l'aide des composes anti-cd40l
WO1998039026A2 (fr) * 1997-03-07 1998-09-11 Biogen, Inc. Procedes d'administration therapeutiques de composes anti-cd40l
US5833987A (en) * 1995-06-07 1998-11-10 Trustees Of Dartmouth College Treatment of T cell mediated autoimmune disorders
WO1999000143A1 (fr) * 1997-06-27 1999-01-07 Biogen, Inc. Therapie de blocage par cd154 pour maladies auto-immunes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672347A (en) * 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US5876950A (en) * 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0555880A2 (fr) * 1992-02-14 1993-08-18 Bristol-Myers Squibb Company Récepteur CD40CR et ses ligands
US5833987A (en) * 1995-06-07 1998-11-10 Trustees Of Dartmouth College Treatment of T cell mediated autoimmune disorders
WO1997017446A2 (fr) * 1995-11-07 1997-05-15 Idec Pharmaceutical Corporation ANTICORPS HUMANISES DIRIGES CONTRE LA gp39 D'ORIGINE HUMAINE, COMPOSITIONS CONTENANT CES ANTICORPS ET LEUR UTILISATION THERAPEUTIQUE
WO1998030240A1 (fr) * 1997-01-10 1998-07-16 Biogen, Inc. Traitement de la nephropathie lupique a l'aide des composes anti-cd40l
WO1998039026A2 (fr) * 1997-03-07 1998-09-11 Biogen, Inc. Procedes d'administration therapeutiques de composes anti-cd40l
WO1999000143A1 (fr) * 1997-06-27 1999-01-07 Biogen, Inc. Therapie de blocage par cd154 pour maladies auto-immunes

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DESAI-MEHTA A ET AL: "Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production", JOURNAL OF CLINICAL INVESTIGATION, NEW YORK, NY, US, vol. 9, no. 97, 1 May 1996 (1996-05-01), pages 2063 - 2073, XP002080040, ISSN: 0021-9738 *
EARLY G ET AL: "Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand White mice", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 157, no. 7, 1 October 1996 (1996-10-01), pages 3159 - 3164, XP002080042, ISSN: 0022-1767 *
GRAY DAVID ET AL: "Memory B cell development but not germinal center formation is impaired by in vivo blockade of CD40-CD40 ligand interaction", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 180, no. 1, 1994, pages 141 - 155, XP002283910, ISSN: 0022-1007 *
KOOTEN C V ET AL: "Functions of CD40 on B cells, dendritic cells and other cells", CURRENT OPINION IN IMMUNOLOGY, CURRENT BIOLOGY LTD, XX, vol. 9, no. 3, June 1997 (1997-06-01), pages 330 - 337, XP004313522, ISSN: 0952-7915 *
MOHAN C ET AL: "INTERACTION BETWEEN CD40 AND ITS LIGAND GP39 IN THE DEVELOPMENT OF MURINE LUPUS NEPHRITIS", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 154, no. 3, 1995, pages 1470 - 1480, XP002062342, ISSN: 0022-1767 *
NOELLE R J ET AL: "A 39-KDA PROTEIN ON ACTIVATED HELPER T CELLS BINDS CD40 AND TRANSDUCES THE SIGNAL FOR COGNATE ACTIVATION OF B CELLS", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 89, July 1992 (1992-07-01), pages 6550 - 6554, XP002941549, ISSN: 0027-8424 *
See also references of WO9951258A1 *

Also Published As

Publication number Publication date
JP2002510643A (ja) 2002-04-09
CN1303301A (zh) 2001-07-11
CN1757413A (zh) 2006-04-12
TWI224969B (en) 2004-12-11
WO1999051258A1 (fr) 1999-10-14
NO20004966D0 (no) 2000-10-02
AU3379699A (en) 1999-10-25
CN1173735C (zh) 2004-11-03
HUP0101689A3 (en) 2004-08-30
HUP0101689A2 (hu) 2001-08-28
CN100352497C (zh) 2007-12-05
KR20010072564A (ko) 2001-07-31
NO20004966L (no) 2000-12-04
AU743824B2 (en) 2002-02-07
EP1067954A1 (fr) 2001-01-17

Similar Documents

Publication Publication Date Title
PT1083889E (pt) Compostos de tetra-hidronaftaleno e sua utilizacao no tratamento de doencas neurodegenerativas
AUPP784398A0 (en) Kidney disease detection and treatment
DE69805438T2 (de) Misch- und ladeöffnung zur medizinischen behandlung
EP1071458A4 (fr) Anticorps humanises et utilisations correspondantes
GB2342111B (en) Emulsion for well and formation treatment
ATE241977T1 (de) Verwendung von anti-mikrotubuli mitteln zur behandlung von entzündlichen darmerkrankungen
AU1462300A (en) Human pan-hcv human monoclonal antibodies
GB9806038D0 (en) Magnetic device for the treatment of fluids
AU6085298A (en) Closed chemically enhanced water treatment system
GB2339905A8 (en) Use of mass-spectromy for detection mutations
HUP0003852A3 (en) Use of highly selective butyrylcholinesterase inhibitors for the treatment and diagnosis of alzheimer's disease and dementias
DE69926685D1 (de) Toner und Bildherstellungsverfahren
AU7676300A (en) Human anti-adipocyte monoclonal antibodies and their use
EP0777474A4 (fr) Procedes de traitement de l'arthrite
AU1181900A (en) Human proteins having hydrophobic domains and dnas encoding these proteins
AU6321400A (en) Human proteins having hydrophobic domains and dnas encoding these proteins
HK1041827B (zh) 用於治療雌激素依賴性疾病的化合物以及製備和使用上述化合物的方法
AU3760400A (en) Methods and reagents for the diagnosis and treatment of multiple sclerosis
AU4196697A (en) Use of igf-i for the treatment of polycystic kidney disease and related indications
AU5249800A (en) Human proteins having hydrophobic domains and dnas encoding these proteins
HUP9700676A3 (en) Anti-fas recombinante antibodies and dna coding thereof
EP1109929A4 (fr) Procedes permettant de diagnostiquer le syndrome renal de perte de sel et la maladie d'alzheimer, et procedes de traitementcorrespondants
FR2771727B1 (fr) Defluoruration d'eaux usees
HUP0101689A3 (en) Use of anti-gp39 antibodies for treatment and/or reversal of lupus and associated kidney disease
EP1107778A4 (fr) Traitement d'etats maladifs

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20001102

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI NL PT SE

RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 07K 16/18 B

Ipc: 7C 07K 14/525 B

Ipc: 7C 07K 14/52 B

Ipc: 7A 61K 39/395 B

Ipc: 7C 07K 16/28 B

Ipc: 7A 61K 38/17 A

A4 Supplementary search report drawn up and despatched

Effective date: 20040630

17Q First examination report despatched

Effective date: 20050127

17Q First examination report despatched

Effective date: 20050127

17Q First examination report despatched

Effective date: 20050127

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090415